Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch
March 09, 2022 07:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering
March 08, 2022 11:45 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat...
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
March 02, 2022 07:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma
February 28, 2022 09:12 ET
|
Akari Therapeutics Plc
Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program relevant to both military and civilian trauma...
Akari Therapeutics to Present at BIO CEO & Investor Conference
February 11, 2022 07:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases
January 26, 2022 08:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies
January 19, 2022 08:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
January 04, 2022 07:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering
December 30, 2021 11:03 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat...
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress
December 03, 2021 07:45 ET
|
Akari Therapeutics Plc
Sites opened in Phase III study of nomacopan in bullous pemphigoid (BP)Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)...